SCHEMBL3471069

SCHEMBL3471069

CCN(c1ccccc1)S(=O)(=O)c1ccc(-c2cc(C(F)(F)F)n(C)n2)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.54
PTGES2 Q9H7Z7 1/20 0.53
GAA P10253 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
POLB P06746 1/20 0.49
ALDH1A1 P00352 1/20 0.47
NPC1 O15118 2/20 0.45
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 3/20 0.41
RORC P51449 2/20 0.40
GALR3 O60755 1/20 0.40
TSHR P16473 2/20 0.39
MAPK1 P28482 2/20 0.39
HSD17B10 Q99714 1/20 0.39
RAB9A P51151 1/20 0.39
NR1I2 O75469 1/20 0.37
RORA P35398 1/20 0.37
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3474698 0.90 NPC1 (0.58) TP53PTGES2GAAL3MBTL1POLB
SCHEMBL3478666 0.82 NPC1 (0.49) TP53PTGES2GAAL3MBTL1POLB
SCHEMBL1594800 0.81 GAA (0.61) TP53PTGES2GAAL3MBTL1POLB
SCHEMBL5232747 0.78 GAA (0.47) TP53PTGES2GAAL3MBTL1POLB
SCHEMBL1593778 0.76 PTGES2 (0.67) PTGES2GAAL3MBTL1POLBALDH1A1
SCHEMBL2633819 0.76 GAA (0.67) PTGES2GAAL3MBTL1POLBALDH1A1
SCHEMBL3010846 0.76 GAA (0.64) PTGES2GAAL3MBTL1POLBALDH1A1
SCHEMBL3461026 0.76 ITGB1 (0.64) PTGES2GAAL3MBTL1POLBALDH1A1
SCHEMBL1593801 0.75 ALDH1A1 (0.67) PTGES2GAAL3MBTL1POLBALDH1A1
SCHEMBL1593511 0.72 GAA (0.61) PTGES2GAAL3MBTL1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 TP53 4318/4885PTGES2 1035/4885GAA 2305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.